

Optimization of Surgical Treatment by Autoplasty in Patients with Primary Pterygium

Boboev Siyovush Saidavzalzoda

Assistant Professor, Department of Ophthalmology, Samarkand State Medical University

Received: 2025, 15, Feb
Accepted: 2025, 21, Mar
Published: 2025, 08, Apr

Copyright © 2025 by author(s) and BioScience Academic Publishing. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).



Open Access

<http://creativecommons.org/licenses/by/4.0/>

Annotation: Pterygium is a pathological growth of the conjunctiva on the cornea, which can lead to decreased vision, discomfort and cosmetic defects. In the conditions of Uzbekistan, where solar activity, dry climate and dust factors have a significant impact on eye health, pterygium is a fairly common disease. Surgical treatment remains the main method of combating pterygium, but the relapse rate after standard surgical methods remains high. The autoplasmic method, in which conjunctival autotransplantation is transplanted into the pterygium removal area, is a promising method that can significantly reduce the relapse rate. Optimization of this method, taking into account regional characteristics, requires more in-depth study in the context of Uzbekistan.

Purpose of the study

To evaluate the clinical effectiveness of the autoplasmic method in the surgical treatment of primary pterygium in patients in Uzbekistan and to propose optimized approaches to reducing the incidence of relapses and improving patient rehabilitation.

Materials and methods of research

Study population: The study included 20 patients diagnosed with primary pterygium who were treated in ophthalmological clinics of Uzbekistan between 2022 and 2024. The average age of patients was 45 years, including 12 women and 8 men. All patients were diagnosed with a progressive form of pterygium with clinical symptoms such as eye irritation, redness, lacrimation, and decreased visual acuity.

Methods of diagnosis and assessment of the condition:

Ophthalmoscopy and biomicroscopy were used to study in detail the structure of the eyeball and the extent of pterygium growth.

Keratotopography to assess the impact of pterygium on the cornea and visual function.

Evaluation of recurrences and postoperative complications was carried out within 12 months after surgery.

Surgical treatment method: All patients underwent surgical removal of pterygium followed by autoplasmic conjunctival flap. For autoplasmic, tissue from the upper lateral segment of the conjunctiva was used, which was fixed without sutures using bioglue. This method reduced the risk of inflammatory reactions and accelerated healing.

Statistical analysis: Descriptive statistics methods were used to evaluate the results, calculating the frequency of relapses and the occurrence of complications.

Results and discussion

As a result of surgical treatment using autoplasmic method, all 20 patients showed significant improvement both in functional and cosmetic terms. Already in the first week after surgery, patients noted a significant reduction in symptoms of irritation, redness and lacrimation. All patients noted an improvement in visual acuity associated with the elimination of pterygium growth.

Recurrence of pterygium was registered only in 2 patients (10%) within 12 months after surgery, which is significantly lower than in traditional surgical methods, where the recurrence rate can reach 30-40%. In these patients, the recurrence developed within the first 6 months after surgery, which is probably due to individual characteristics of tissue regeneration and immune response. In both cases, a second operation was performed, also using the autograft method.

Complications such as infection, inflammation or transplant rejection were not registered. The use of bioglue to fix the transplant allowed to reduce the time of the operation and avoid the risk of complications associated with suturing.

90% of patients showed complete rehabilitation within 2 weeks after surgery. Restoration of normal function and shape of the eye was observed in all patients. The cosmetic effect was also highly appreciated by patients, which emphasizes the importance of choosing the autoplasmic method for treating pterygium.

Conclusions

1. The autoplasmic method in the treatment of primary pterygium has shown high clinical effectiveness, providing a significant reduction in the frequency of relapses and rapid restoration of visual functions.
2. The use of bioglue to fix the transplant is a safe and effective method that minimizes the risk of complications and accelerates healing.
3. Optimization of surgical treatment of pterygium using autoplasty is the preferred method in the conditions of Uzbekistan, taking into account the climatic and social factors that contribute to the development of the disease.
4. Further studies involving larger patient samples are needed to clarify the long-term efficacy and safety of this method.

Thus, the autoplasmic method in the treatment of primary pterygium can be considered the most optimal in terms of preventing relapses and improving the quality of life of patients in Uzbekistan.

Reference:

1. Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З. (2016). Эффективность комбинированного лечения пациентов с центральной серозной хориоретинопатией. Вестник Башкирского государственного медицинского университета, (2), 64-66.

2. Andryev S. et al. Experience with the use of memantine in the treatment of cognitive disorders //Science and innovation. – 2023. – T. 2. – №. D11. – C. 282-288.
3. Antsiborov S. et al. Association of dopaminergic receptors of peripheral blood lymphocytes with a risk of developing antipsychotic extrapyramidal diseases //Science and innovation. – 2023. – T. 2. – №. D11. – C. 29-35.
4. Asanova R. et al. Features of the treatment of patients with mental disorders and cardiovascular pathology //Science and innovation. – 2023. – T. 2. – №. D12. – C. 545-550.
5. Begbudiyev M. et al. Integration of psychiatric care into primary care //Science and innovation. – 2023. – T. 2. – №. D12. – C. 551-557.
6. Bo'Riyev B. et al. Features of clinical and psychopathological examination of young children //Science and innovation. – 2023. – T. 2. – №. D12. – C. 558-563.
7. Borisova Y. et al. Concomitant mental disorders and social functioning of adults with high-functioning autism/asperger syndrome //Science and innovation. – 2023. – T. 2. – №. D11. – C. 36-41.
8. Ivanovich U. A. et al. Efficacy and tolerance of pharmacotherapy with antidepressants in non-psychotic depressions in combination with chronic brain ischemia //Science and Innovation. – 2023. – T. 2. – №. 12. – C. 409-414.
9. Nikolaevich R. A. et al. Comparative effectiveness of treatment of somatoform diseases in psychotherapeutic practice //Science and Innovation. – 2023. – T. 2. – №. 12. – C. 898-903.
10. Novikov A. et al. Alcohol dependence and manifestation of autoaggressive behavior in patients of different types //Science and innovation. – 2023. – T. 2. – №. D11. – C. 413-419.
11. Pachulia Y. et al. Assessment of the effect of psychopathic disorders on the dynamics of withdrawal syndrome in synthetic cannabinoid addiction //Science and innovation. – 2023. – T. 2. – №. D12. – C. 240-244.
12. Pachulia Y. et al. Neurobiological indicators of clinical status and prognosis of therapeutic response in patients with paroxysmal schizophrenia //Science and innovation. – 2023. – T. 2. – №. D12. – C. 385-391.
13. Pogosov A. et al. Multidisciplinary approach to the rehabilitation of patients with somatized personality development //Science and innovation. – 2023. – T. 2. – №. D12. – C. 245-251.
14. Pogosov A. et al. Rational choice of pharmacotherapy for senile dementia //Science and innovation. – 2023. – T. 2. – №. D12. – C. 230-235.
15. Pogosov S. et al. Gnostic disorders and their compensation in neuropsychological syndrome of vascular cognitive disorders in old age //Science and innovation. – 2023. – T. 2. – №. D12. – C. 258-264.
16. Pogosov S. et al. Prevention of adolescent drug abuse and prevention of yatrogenia during prophylaxis //Science and innovation. – 2023. – T. 2. – №. D12. – C. 392-397.
17. Pogosov S. et al. Psychogenetic properties of drug patients as risk factors for the formation of addiction //Science and innovation. – 2023. – T. 2. – №. D12. – C. 186-191.
18. Sedenkov V. et al. Clinical and socio-demographic characteristics of elderly patients with suicide attempts //Science and innovation. – 2023. – T. 2. – №. D12. – C. 273-277.
19. Sedenkov V. et al. Modern methods of diagnosing depressive disorders in neurotic and affective disorders //Science and innovation. – 2023. – T. 2. – №. D12. – C. 361-366.
20. Zukhridinovna, Z. D. (2022). Modern aspects of neuroprotective treatment in hypertensive retinopathy.

21. Jalalova, D., Raxmonov, X., & Shernazarov, F. (2022). THE ROLE OF C-REACTIVE PROTEIN IN THE PATHOGENESIS OF VISUAL VASCULAR DISEASES IN PATIENTS WITH ARTERIAL HYPERTENSION. *Science and Innovation*, 1(8), 114-121.
22. Jalalova, D., Raxmonov, X., & Shernazarov, F. (2022). SIGNIFICANCE OF ENDOTHELIAL DYSFUNCTION IN THE DEVELOPMENT OF RETINOPATHY IN PATIENTS WITH AH AND WAYS OF ITS CORRECTION. *Science and Innovation*, 1(8), 101-113.
23. Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). COMBINED DENTAL AND EYE PATHOLOGY. *Science and innovation*, 1(8), 91-100.
24. Саттарова, Х. С., Жалалова, Д. З., & Бектурдиев, Ш. С. (2011). Причины слепоты и слабовидения при сахарном диабете. *Академический журнал Западной Сибири*, (6), 27-28.
25. Arunachalam, S. (2008). The science race continues in Asia. *Current Science* (00113891), 94(7).
26. Zukhriddinovna, Z. D. (2022). Development of Classification Criteria for Neuroretinal Ischemia in Arterial Hypertension. *Central Asian Journal of Medical and Natural Science*, 3(3), 59-65.
27. Жалалова, Д. З., & Исмоилов, Ж. Ж. (2024). ТЕОРЕТИЧЕСКОЕ ОБОСНОВАНИЕ ИССЛЕДОВАНИЯ ЭНДОТЕЛИНА-1 И Д-ДИМЕРОВ В КРОВИ И СЛЕЗНОЙ ЖИДКОСТИ ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ АНГИОРЕТИНОПАТИЕЙ. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 3(3), 294-299.
28. Киселева, Т. Н., Ежов, М. В., Аджемян, Н. А., Танковский, В. Э., & Ильина, Н. В. (2016). Особенности регионарного глазного кровотока при артериальной гипертензии I-II степени и субклиническом атеросклерозе. *Российский офтальмологический журнал*, 9(3), 26-33.
29. Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от иммунного статуса пациентов. *междисциплинарный подход по заболеваниям органов головы и шеи*, 103.
30. Дроздова, Е. А., & Хохлова, Д. Ю. (2015). Морфометрическая характеристика макулярной зоны у пациентов с окклюзией вен сетчатки по данным оптической когерентной томографии. *Медицинский вестник Башкортостана*, 10(2 (56)), 64-67.
31. Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). СОЧЕТАННАЯ СТОМАТОЛОГИЧЕСКАЯ И ГЛАЗНАЯ ПАТОЛОГИЯ. *Science and innovation*, 1(D8), 91-100.
32. Zhang, S., & Melander, S. (2014). Varicose veins: Diagnosis, management, and treatment. *The Journal for Nurse Practitioners*, 10(6), 417-424.
33. Жалалова, Д. З., & Бабаев, С. А. (2024). РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И Д-ДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 3(3), 300-307.
34. Zukhriddinovna, Z. D. (2022). Development of Classification Criteria for Neuroretinal Ischemia in Arterial Hypertension. *Central Asian Journal of Medical and Natural Science*, 3(3), 59-65.